|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang CM, Ji S, Li Y, Fu LY, Jiang T and
Meng FD: β-Catenin promotes cell proliferation, migration, and
invasion but induces apoptosis in renal cell carcinoma. Onco
Targets Ther. 10:711–724. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu J, Zhang S, Shan J, Hu Z, Liu X, Chen
L, Ren X, Yao L, Sheng H, Li L, et al: Elevated HMGA2 expression is
associated with cancer aggressiveness and predicts poor outcome in
breast cancer. Cancer Lett. 376:284–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Piscuoglio S, Zlobec I, Pallante P, Sepe
R, Esposito F, Zimmermann A, Diamantis I, Terracciano L, Fusco A
and Karamitopoulou E: HMGA1 and HMGA2 protein expression correlates
with advanced tumour grade and lymph node metastasis in pancreatic
adenocarcinoma. Histopathology. 60:397–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parameswaran S, Xia X, Hegde G and Ahmad
I: Hmga2 regulates self-renewal of retinal progenitors.
Development. 141:4087–4097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pallante P, Sepe R, Puca F and Fusco A:
High mobility group a proteins as tumor markers. Front Med
(Lausanne). 2:152015.PubMed/NCBI
|
|
7
|
Na N, Si T, Huang Z, Miao B, Hong L, Li H
and Qiu J and Qiu J: High expression of HMGA2 predicts poor
survival in patients with clear cell renal cell carcinoma. Onco
Targets Ther. 9:7199–7205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang W, Li J, Guo X, Zhao Y and Yuan X:
miR-663a inhibits hepatocellular carcinoma cell proliferation and
invasion by targeting HMGA2. Biomed Pharmacother. 81:431–438. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kala R, Peek GW, Hardy TM and Tollefsbol
TO: MicroRNAs: An emerging science in cancer epigenetics. J Clin
Bioinforma. 3:62013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bijnsdorp IV, Hodzic J, Lagerweij T,
Westerman B, Krijgsman O, Broeke J, Verweij F, Nilsson RJ,
Rozendaal L, van Beusechem VW, et al: miR-129-3p controls
centrosome number in metastatic prostate cancer cells by repressing
CP110. Oncotarget. 7:16676–16687. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu X, Wu G, Wu Z, Yao X and Li G: MiR-200a
suppresses the proliferation and metastasis in pancreatic ductal
adenocarcinoma through downregulation of DEK gene. Transl Oncol.
9:25–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan C, Lin Y, Mao Y, Huang Z, Liu AY, Ma
H, Yu D, Maitikabili A, Xiao H, Zhang C, et al: MicroRNA-543
suppresses colorectal cancer growth and metastasis by targeting
KRAS, MTA1 and HMGA2. Oncotarget. 7:21825–21839. 2016.PubMed/NCBI
|
|
14
|
Martínez-Salamanca JI, Huang WC, Millán I,
Bertini R, Bianco FJ, Carballido JA, Ciancio G, Hernández C,
Herranz F, Haferkamp A, et al: Prognostic impact of the 2009
UICC/AJCC TNM staging system for renal cell carcinoma with venous
extension. Eur Urol. 59:120–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rao X, Huang X, Zhou Z and Lin X: An
improvement of the 2^(-delta delta CT) method for quantitative
real-time polymerase chain reaction data analysis. Biostat
Bioinforma Biomath. 3:71–85. 2013.PubMed/NCBI
|
|
16
|
Chow TF, Youssef YM, Lianidou E, Romaschin
AD, Honey RJ, Stewart R, Pace KT and Yousef GM: Differential
expression profiling of microRNAs and their potential involvement
in renal cell carcinoma pathogenesis. Clin Biochem. 43:150–158.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan XD, Gu DH, Mao JH, Zhu H, Chen X,
Zheng B and Shan Y: Concurrent inhibition of mTORC1 and mTORC2 by
WYE-687 inhibits renal cell carcinoma cell growth in vitro and in
vivo. PLoS One. 12:e1725552017.
|
|
18
|
Wu SW, Chen PN, Lin CY, Hsieh YS and Chang
HR: Everolimus suppresses invasion and migration of renal cell
carcinoma by inhibiting FAK activity and reversing epithelial to
mesenchymal transition in vitro and in vivo. Environ Toxicol.
32:1888–1898. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI,
Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, et al: The
international metastatic renal cell carcinoma database consortium
model as a prognostic tool in patients with metastatic renal cell
carcinoma previously treated with first-line targeted therapy: A
population-based study. Lancet Oncol. 16:293–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chatzizacharias NA, Rosich-Medina A,
Dajani K, Harper S, Huguet E, Liau SS, Praseedom RK and Jah A:
Surgical management of hepato-pancreatic metastasis from renal cell
carcinoma. World J Gastrointest Oncol. 9:70–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang T, Li M, Li Q, Guo Z, Sun X, Zhang
X, Liu Y, Yao W and Xiao P: MicroRNA-98-5p inhibits cell
proliferation and induces cell apoptosis in hepatocellular
carcinoma via targeting IGF2BP1. Oncol Res. 25:1117–1127. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okato A, Goto Y, Kurozumi A, Kato M,
Kojima S, Matsushita R, Yonemori M, Miyamoto K, Ichikawa T and Seki
N: Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in
prostate cancer. Int J Oncol. 49:111–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin Y, Liu AY, Fan C, Zheng H, Li Y, Zhang
C, Wu S, Yu D, Huang Z, Liu F, et al: MicroRNA-33b Inhibits Breast
Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1. Sci Rep.
5:99952015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin H and Wang W: MicroRNA-539 suppresses
osteosarcoma cell invasion and migration in vitro and targeting
Matrix metallopeptidase-8. Int J Clin Exp Pathol. 8:8075–8082.
2015.PubMed/NCBI
|
|
25
|
Zhang H, Li S, Yang X, Qiao B, Zhang Z and
Xu Y: miR-539 inhibits prostate cancer progression by directly
targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bobowicz M, Skrzypski M, Czapiewski P,
Marczyk M, Maciejewska A, Jankowski M, Szulgo-Paczkowska A,
Zegarski W, Pawłowski R, Polańska J, et al: Prognostic value of
5-microRNA based signature in T2-T3N0 colon cancer. Clin Exp
Metastasis. 33:765–773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zou Q, Xiong L, Yang Z, Lv F, Yang L and
Miao X: Expression levels of HMGA2 and CD9 and its
clinicopathological significances in the benign and malignant
lesions of the gallbladder. World J Surg Oncol. 10:922012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z and You
T: HMGA2 induces transcription factor Slug expression to promote
epithelial-to-mesenchymal transition and contributes to colon
cancer progression. Cancer Lett. 355:130–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia YY, Yin L, Jiang N, Guo WJ, Tian H,
Jiang XS, Wu J, Chen M, Wu JZ and He X: Downregulating HMGA2
attenuates epithelial-mesenchymal transition-induced invasion and
migration in nasopharyngeal cancer cells. Biochem Biophys Res
Commun. 463:357–363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shi Z, Wu D, Tang R, Li X, Chen R, Xue S,
Zhang C and Sun X: Silencing of HMGA2 promotes apoptosis and
inhibits migration and invasion of prostate cancer cells. J Biosci.
41:229–236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie HX, Xu ZY, Tang JN, DU YA, Huang L, Yu
PF and Cheng XD: Effect of Huaier on the proliferation and
apoptosis of human gastric cancer cells through modulation of the
PI3K/AKT signaling pathway. Exp Ther Med. 10:1212–1218. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deng W, Zhang Y, Gu L, Cui J, Duan B, Wang
Y and Du J: Heat shock protein 27 downstream of P38-PI3K/Akt
signaling antagonizes melatonin-induced apoptosis of SGC-7901
gastric cancer cells. Cancer Cell Int. 16:52016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tan L, Wei X, Zheng L, Zeng J, Liu H, Yang
S and Tan H: Amplified HMGA2 promotes cell growth by regulating Akt
pathway in AML. J Cancer Res Clin Oncol. 142:389–399. 2016.
View Article : Google Scholar : PubMed/NCBI
|
